CSPC Pharmaceutical Group Ltd. (CSPCY)

Overview

CSPC Pharmaceutical Group Limited, established in 1992 and headquartered in Shijiazhuang, the People's Republic of China, is a prominent investment holding company specializing in the pharmaceutical sector. The company stands out for its comprehensive involvement in researching, developing, manufacturing, and distributing pharmaceutical products across a wide geographical stretch that includes the People's Republic of China, other Asian regions, North America, Europe, and beyond in the global market. Operating through its strategic divisions—Finished Drugs, Bulk Products, and Functional Food and Others—CSPC Pharmaceutical has cemented its reputation as a leading provider of a variety of pharmaceutical solutions. A significant milestone in the company's history is its strategic partnership with Pfizer Inc., aimed at launching a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, showcasing its commitment to contributing to global health crises solutions. Originally known as China Pharmaceutical Group Limited, the company rebranded to CSPC Pharmaceutical Group Limited in March 2013 to better reflect its expansive scope and ambitions.

Products and Services

• NBP soft capsules and injections: Designed for the treatment of acute ischemic stroke, offering crucial intervention in the early stages of stroke management.
• Oulaining capsules and injections: Prescribed for mild to moderate memory and mental impairment, enhancing cognitive functions in affected individuals.
• Enxi: A medication aimed at treating adult idiopathic Parkinson's disease, offering relief and improving the quality of life for patients.
• Duomeisu: Focused on the treatment of lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors, showcasing the company's dedication to cancer care.
• Jinyouli: Developed to prevent leucopenia and infection induced by chemotherapy, supporting patients through their cancer treatment process.
• Keaili: Another of the company’s oncology offerings, specifically targeting breast cancer treatment.
• Antibiotics, Vitamin C, and Caffeine APIs: Critical components in the development of a range of pharmaceutical applications, highlighting CSPC's diverse approach to health solutions.
• Functional food and glucose products: Expanding beyond pharmaceuticals, these offerings cater to the broader health and wellness sector, providing nutritional and health maintenance options.
• Healthcare services: Beyond products, CSPC offers a spectrum of healthcare services, reinforcing its comprehensive approach towards healthcare provision and patient support.